nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—EIF4E—pancreas—bile duct cancer	0.0179	0.199	CbGeAlD
Sirolimus—EIF4E—liver—bile duct cancer	0.0114	0.127	CbGeAlD
Sirolimus—MTOR—pancreas—bile duct cancer	0.00694	0.0771	CbGeAlD
Sirolimus—FKBP1A—pancreas—bile duct cancer	0.00624	0.0693	CbGeAlD
Sirolimus—FGF2—lymph node—bile duct cancer	0.00533	0.0593	CbGeAlD
Sirolimus—CYP3A7—liver—bile duct cancer	0.00491	0.0546	CbGeAlD
Sirolimus—MTOR—liver—bile duct cancer	0.00441	0.0491	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—liver—bile duct cancer	0.00418	0.0464	CbGeAlD
Sirolimus—FKBP1A—liver—bile duct cancer	0.00397	0.0441	CbGeAlD
Sirolimus—SLC47A1—liver—bile duct cancer	0.00341	0.0379	CbGeAlD
Sirolimus—MTOR—lymph node—bile duct cancer	0.00338	0.0376	CbGeAlD
Sirolimus—SLCO1B1—liver—bile duct cancer	0.00337	0.0374	CbGeAlD
Sirolimus—FKBP1A—lymph node—bile duct cancer	0.00304	0.0338	CbGeAlD
Sirolimus—CYP3A5—pancreas—bile duct cancer	0.00272	0.0302	CbGeAlD
Sirolimus—SLC47A1—lymph node—bile duct cancer	0.00262	0.0291	CbGeAlD
Sirolimus—CYP3A5—liver—bile duct cancer	0.00173	0.0192	CbGeAlD
Sirolimus—ABCB1—pancreas—bile duct cancer	0.00144	0.016	CbGeAlD
Sirolimus—CYP3A4—liver—bile duct cancer	0.0013	0.0144	CbGeAlD
Sirolimus—ABCB1—liver—bile duct cancer	0.000918	0.0102	CbGeAlD
Sirolimus—ABCB1—lymph node—bile duct cancer	0.000704	0.00783	CbGeAlD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000567	0.000623	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—IL6—bile duct cancer	0.000562	0.000618	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—KRAS—bile duct cancer	0.000558	0.000613	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.000557	0.000612	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—NRAS—bile duct cancer	0.000556	0.000611	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—KRAS—bile duct cancer	0.000555	0.00061	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—bile duct cancer	0.000555	0.00061	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—IL6—bile duct cancer	0.000555	0.000609	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFBR2—bile duct cancer	0.000554	0.000609	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—KRAS—bile duct cancer	0.000552	0.000607	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—NRAS—bile duct cancer	0.000552	0.000606	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—KRAS—bile duct cancer	0.00055	0.000604	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—HRAS—bile duct cancer	0.000548	0.000602	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.000548	0.000602	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—bile duct cancer	0.000548	0.000602	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—bile duct cancer	0.000548	0.000602	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—TGFB1—bile duct cancer	0.000547	0.000601	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—bile duct cancer	0.000543	0.000596	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—bile duct cancer	0.000542	0.000595	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—ERBB2—bile duct cancer	0.000538	0.000591	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.000538	0.000591	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—bile duct cancer	0.000535	0.000588	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP2—bile duct cancer	0.000534	0.000587	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.000532	0.000585	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFBR2—bile duct cancer	0.000529	0.000581	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—HRAS—bile duct cancer	0.000527	0.00058	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000525	0.000577	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SMAD4—bile duct cancer	0.000524	0.000576	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.000522	0.000574	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—HRAS—bile duct cancer	0.000519	0.00057	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KRAS—bile duct cancer	0.000517	0.000568	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KRAS—bile duct cancer	0.000517	0.000568	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.000517	0.000568	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—KRAS—bile duct cancer	0.000513	0.000563	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—GNAS—bile duct cancer	0.00051	0.000561	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.000508	0.000558	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—bile duct cancer	0.000507	0.000557	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KRAS—bile duct cancer	0.000506	0.000556	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—IL6—bile duct cancer	0.000505	0.000555	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.000505	0.000554	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—FAR2—bile duct cancer	0.000503	0.000553	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—bile duct cancer	0.000503	0.000552	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000502	0.000552	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SMAD4—bile duct cancer	0.000501	0.00055	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—HRAS—bile duct cancer	0.000497	0.000546	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—IDH2—bile duct cancer	0.000491	0.000539	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000485	0.000533	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000483	0.000531	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KRAS—bile duct cancer	0.000479	0.000526	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RNF43—bile duct cancer	0.000477	0.000525	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—HRAS—bile duct cancer	0.000477	0.000524	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—IL6—bile duct cancer	0.000475	0.000522	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—KRAS—bile duct cancer	0.000475	0.000522	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—HRAS—bile duct cancer	0.000474	0.000521	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—bile duct cancer	0.000472	0.000519	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.000472	0.000519	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—bile duct cancer	0.00047	0.000516	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ERBB2—bile duct cancer	0.000468	0.000515	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—HRAS—bile duct cancer	0.000467	0.000514	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000462	0.000508	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.000461	0.000506	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TGFB1—bile duct cancer	0.000458	0.000504	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.000458	0.000503	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—IL6—bile duct cancer	0.000454	0.000499	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—bile duct cancer	0.000452	0.000496	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—IDH2—bile duct cancer	0.000451	0.000495	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—IL6—bile duct cancer	0.000449	0.000494	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—IL6—bile duct cancer	0.000447	0.000491	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—bile duct cancer	0.00044	0.000483	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00044	0.000483	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—bile duct cancer	0.00044	0.000483	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—bile duct cancer	0.000436	0.000479	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERBB2—bile duct cancer	0.000433	0.000476	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.000432	0.000475	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—bile duct cancer	0.00043	0.000472	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—IDH1—bile duct cancer	0.000422	0.000464	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000421	0.000462	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—bile duct cancer	0.000421	0.000462	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—bile duct cancer	0.000421	0.000462	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFBR2—bile duct cancer	0.00042	0.000461	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HGF—bile duct cancer	0.000418	0.000459	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—bile duct cancer	0.000417	0.000458	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ERBB2—bile duct cancer	0.000414	0.000454	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.000413	0.000454	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—bile duct cancer	0.000412	0.000452	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—NRAS—bile duct cancer	0.000409	0.00045	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—bile duct cancer	0.000407	0.000447	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—bile duct cancer	0.000404	0.000443	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP9—bile duct cancer	0.000402	0.000441	CbGpPWpGaD
Sirolimus—FGF2—Disease—SMAD4—bile duct cancer	0.000397	0.000437	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERBB2—bile duct cancer	0.000397	0.000436	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NOS2—bile duct cancer	0.00039	0.000429	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000389	0.000428	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFBR2—bile duct cancer	0.000388	0.000426	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—IDH1—bile duct cancer	0.000387	0.000426	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—IL6—bile duct cancer	0.000386	0.000424	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNAS—bile duct cancer	0.000374	0.000411	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—bile duct cancer	0.000373	0.00041	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000373	0.00041	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SMAD4—bile duct cancer	0.000367	0.000403	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NRAS—bile duct cancer	0.000356	0.000391	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KRAS—bile duct cancer	0.000352	0.000387	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—bile duct cancer	0.000334	0.000367	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—bile duct cancer	0.000331	0.000364	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NRAS—bile duct cancer	0.00033	0.000362	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—IDH2—bile duct cancer	0.000326	0.000358	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—bile duct cancer	0.000325	0.000357	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.00032	0.000352	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—bile duct cancer	0.000315	0.000346	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	0.000313	0.000344	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFBR2—bile duct cancer	0.000312	0.000342	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FAR2—bile duct cancer	0.00031	0.000341	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HGF—bile duct cancer	0.00031	0.000341	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB2—bile duct cancer	0.000307	0.000337	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—KRAS—bile duct cancer	0.000307	0.000337	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—bile duct cancer	0.000306	0.000336	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—NRAS—bile duct cancer	0.000302	0.000332	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—bile duct cancer	0.0003	0.00033	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—bile duct cancer	0.0003	0.000329	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.000298	0.000327	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOS2—bile duct cancer	0.000296	0.000325	CbGpPWpGaD
Sirolimus—MTOR—Disease—SMAD4—bile duct cancer	0.000295	0.000324	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB2—bile duct cancer	0.000295	0.000324	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFBR2—bile duct cancer	0.000294	0.000323	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB2—bile duct cancer	0.000293	0.000322	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—bile duct cancer	0.000287	0.000315	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—bile duct cancer	0.000287	0.000315	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—bile duct cancer	0.000287	0.000315	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KRAS—bile duct cancer	0.000284	0.000312	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNAS—bile duct cancer	0.000284	0.000312	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB2—bile duct cancer	0.00028	0.000308	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—IDH1—bile duct cancer	0.00028	0.000308	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SLC5A5—bile duct cancer	0.000279	0.000306	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SMAD4—bile duct cancer	0.000278	0.000306	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—bile duct cancer	0.000275	0.000302	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—bile duct cancer	0.000271	0.000298	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000261	0.000287	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—bile duct cancer	0.000261	0.000286	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—bile duct cancer	0.00026	0.000286	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC5A5—bile duct cancer	0.000256	0.000281	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—bile duct cancer	0.000249	0.000274	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—IDH2—bile duct cancer	0.000246	0.00027	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—bile duct cancer	0.000241	0.000265	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—bile duct cancer	0.000241	0.000265	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—bile duct cancer	0.00024	0.000264	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—bile duct cancer	0.000234	0.000257	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000231	0.000254	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—bile duct cancer	0.000231	0.000254	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—bile duct cancer	0.00023	0.000253	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000226	0.000249	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—bile duct cancer	0.000224	0.000246	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—bile duct cancer	0.000223	0.000245	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—bile duct cancer	0.000222	0.000244	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000222	0.000244	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—bile duct cancer	0.000221	0.000243	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—bile duct cancer	0.00022	0.000242	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS2—bile duct cancer	0.000219	0.000241	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFBR2—bile duct cancer	0.000218	0.00024	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—bile duct cancer	0.000217	0.000239	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNAS—bile duct cancer	0.000216	0.000238	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—bile duct cancer	0.000213	0.000234	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—bile duct cancer	0.000213	0.000234	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—IDH1—bile duct cancer	0.000211	0.000232	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNAS—bile duct cancer	0.00021	0.000231	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.00021	0.00023	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—bile duct cancer	0.000207	0.000228	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SMAD4—bile duct cancer	0.000206	0.000227	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—bile duct cancer	0.000206	0.000226	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—bile duct cancer	0.000204	0.000224	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—bile duct cancer	0.000203	0.000224	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—bile duct cancer	0.000201	0.000221	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNAS—bile duct cancer	0.000199	0.000218	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—bile duct cancer	0.000198	0.000218	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—bile duct cancer	0.000194	0.000213	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—bile duct cancer	0.000193	0.000212	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—bile duct cancer	0.000192	0.000211	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000186	0.000205	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC5A5—bile duct cancer	0.000185	0.000203	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—bile duct cancer	0.000183	0.000202	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—bile duct cancer	0.000183	0.000201	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—bile duct cancer	0.000179	0.000196	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—bile duct cancer	0.000176	0.000194	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—bile duct cancer	0.000171	0.000188	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—bile duct cancer	0.000169	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—bile duct cancer	0.000167	0.000183	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—bile duct cancer	0.000165	0.000181	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—bile duct cancer	0.000164	0.00018	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—bile duct cancer	0.000163	0.00018	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—bile duct cancer	0.000163	0.000179	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—bile duct cancer	0.000163	0.000179	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—bile duct cancer	0.000161	0.000177	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—bile duct cancer	0.000158	0.000173	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—bile duct cancer	0.000157	0.000173	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—bile duct cancer	0.000156	0.000172	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—bile duct cancer	0.000156	0.000172	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—bile duct cancer	0.000156	0.000171	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—bile duct cancer	0.000156	0.000171	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—bile duct cancer	0.000154	0.000169	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000151	0.000166	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—bile duct cancer	0.000149	0.000164	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—bile duct cancer	0.000146	0.00016	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—bile duct cancer	0.000145	0.00016	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNAS—bile duct cancer	0.000144	0.000158	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—bile duct cancer	0.000142	0.000157	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC5A5—bile duct cancer	0.000139	0.000153	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—bile duct cancer	0.000136	0.000149	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—bile duct cancer	0.000135	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—bile duct cancer	0.000134	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—bile duct cancer	0.000134	0.000147	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—IDH1—bile duct cancer	0.00013	0.000143	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—bile duct cancer	0.000128	0.000141	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—bile duct cancer	0.000126	0.000138	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—bile duct cancer	0.000124	0.000136	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—bile duct cancer	0.000124	0.000136	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—bile duct cancer	0.00012	0.000131	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—bile duct cancer	0.000118	0.00013	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—bile duct cancer	0.000118	0.00013	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—bile duct cancer	0.000117	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—bile duct cancer	0.000117	0.000128	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—bile duct cancer	0.000116	0.000128	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—bile duct cancer	0.000116	0.000127	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—bile duct cancer	0.000114	0.000126	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—bile duct cancer	0.000114	0.000126	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—bile duct cancer	0.00011	0.000121	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—bile duct cancer	0.000109	0.00012	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNAS—bile duct cancer	0.000108	0.000119	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—bile duct cancer	0.000108	0.000119	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—bile duct cancer	0.000108	0.000119	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—bile duct cancer	0.000107	0.000117	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—bile duct cancer	0.000102	0.000112	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—bile duct cancer	9.95e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—bile duct cancer	9.91e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—bile duct cancer	9.52e-05	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—bile duct cancer	9.19e-05	0.000101	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—bile duct cancer	9.06e-05	9.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—bile duct cancer	8.79e-05	9.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—bile duct cancer	8.79e-05	9.66e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—bile duct cancer	8.67e-05	9.53e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC5A5—bile duct cancer	8.59e-05	9.44e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—bile duct cancer	8.3e-05	9.12e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—bile duct cancer	8.17e-05	8.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—bile duct cancer	8.01e-05	8.8e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—bile duct cancer	7.71e-05	8.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—bile duct cancer	7.57e-05	8.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—bile duct cancer	6.73e-05	7.39e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNAS—bile duct cancer	6.68e-05	7.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—bile duct cancer	6.43e-05	7.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—bile duct cancer	6.16e-05	6.77e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—bile duct cancer	5.82e-05	6.39e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—bile duct cancer	3.58e-05	3.94e-05	CbGpPWpGaD
